United Kingdom Archives

News and Trends 9 Feb 2023

Cell and Gene Therapy Catapult boost for life science campus

The Cell and Gene Therapy Catapult (CGT Catapult), an independent U.K. innovation and technology organization specializing in the advancement of cell and gene therapies, has announced its involvement in the development of a major new campus for life science businesses in Stevenage. The new campus was announced by UBS Asset Management’s Real Estate & Private […]

February 9, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 7 Feb 2023

Evonetix closes $24M financing

Evonetix Ltd, a synthetic biology company bringing semiconductor technology to DNA synthesis, has completed a $24 million financing round, extending its total series B funding to over $54 million. This fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also participating in the round. The […]

February 7, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 3 Feb 2023

UK approval for AbbVie Crohn’s disease drug

AbbVie has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved RINVOQ (upadacitinib), a janus kinase (JAK) inhibitor, for the treatment of adult patients with moderately to severely active Crohn’s disease (CD) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biological agent. […]

February 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 1 Feb 2023

Advancing cancer care with 3D genomics

By Oxford BioDynamics Cancer care is in urgent need of effective tests to determine the best approach for personalized medicine. Practical, new solutions exploiting the power of 3D genomics are emerging. Cancer is a vastly complex, multidimensional disease marked by the uncontrolled proliferation of cells. Many intertwined layers of biological systems give rise to the […]

February 1, 2023 - 7 minutesmins - By External Contributor

News and Trends 31 Jan 2023

BiVictriX announces positive data from leukemia study

BiVictriX Therapeutics plc has announced positive in vivo data from a toxicity evaluation study with BVX001, the company’s lead program, compared to gemtuzumab ozogamicin (GO). GO, marketed as Mylotarg, is the only approved antibody drug conjugate (ADC) indicated for the treatment of acute myeloid leukemia (AML). One of the significant toxicities of GO is the […]

January 31, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 24 Jan 2023

Ubiquigent and University of Glasgow to collaborate on drug discovery

Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neruodegenerative, renal, and cardiovascular diseases. Overseen by structural biology experts […]

January 24, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 24 Jan 2023

Funding for university to develop new motor neuron disease therapies

Medical research charity LifeArc, the Motor Neurone Disease Association (MND Association) and the My Name’5 Doddie Foundation have jointly awarded £1 million ($1.2 million) to researchers at University College London (UCL) to progress two pioneering new therapies that could help transform the lives of those living with motor neuron disease (MND). The research grants are […]

January 24, 2023 - 4 minutesmins - By Jim Cornall

Jose Bengoechea professor Queen’s University in Belfast Northern Ireland

Interview 24 Jan 2023

Watch: Queen’s University tackling antimicrobial resistance

One of the biggest global challenges facing healthcare systems is bacteria and viruses becoming resistant to drugs. Antimicrobial resistance (AMR) contributes to the deaths of around 700,000 people annually. Without new drugs or ways of dealing with AMR, the number of deaths could reach as many as 10 million per year by 2050 and cause […]

January 24, 2023 - 2 minutesmins - By Jim Cornall

Interview 23 Jan 2023

Watch: pHion Therapeutics talks about next-generation mRNA vaccines

pHion Therapeutics is a U.K.-based vaccine development company. It is developing a pipeline of therapeutic and prophylactic vaccines focussed on viral infections and oncology. The company’s proprietary RALA platform can deliver anionic molecules, such as mRNA and DNA, in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. The RALA peptide-based […]

January 23, 2023 - 1 minutemin - By Jim Cornall

News and Trends 19 Jan 2023

Cloned maggot enzyme wound treatment moves closer to reality

Cambridge U.K. biotech company SolasCure, which is developing a wound cleaning technology, has published its pre-clinical results with the International Wound Journal, showing preliminary evidence that supports its new enzymatic debridement product for use in chronic wounds. Debridement, the removal of all infected and nonviable tissue, is a crucial prerequisite for a wound to heal. […]

January 19, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 17 Jan 2023

Multus Biotechnology closes $9.5M funding to bring cultivated meat closer to price parity

Multus Biotechnology Limited, a U.K.-based start-up creating ingredients for the affordable scale-up of cellular agriculture, has completed a £7.9 million ($9.5 million) funding round led by Mandi Ventures. Other investors include SOSV, Big Idea Ventures and SynBioVen, alongside Asahi Kasei, a global company that contributes to a sustainable society by tackling evolving challenges in materials, […]

January 17, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 17 Jan 2023

TTP spinout Cellular Origins to focus on cell and gene therapies

TTP plc, a technology and product development company, has announced the launch of Cellular Origins. Cellular Origins is a TTP spin-out, created to enable scalable, cost-effective and efficient manufacture of cell and gene therapies. Cellular Origins’ proprietary technology addresses the current barriers associated with the manufacture of advanced therapies that are in late-stage development, enabling […]

January 17, 2023 - 3 minutesmins - By Jim Cornall

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

Cell and Gene Therapy Catapult boost for life science campus

Evonetix closes $24M financing

UK approval for AbbVie Crohn’s disease drug

Advancing cancer care with 3D genomics

BiVictriX announces positive data from leukemia study

Ubiquigent and University of Glasgow to collaborate on drug discovery

Funding for university to develop new motor neuron disease therapies

Watch: Queen’s University tackling antimicrobial resistance

Watch: pHion Therapeutics talks about next-generation mRNA vaccines

Cloned maggot enzyme wound treatment moves closer to reality

Multus Biotechnology closes $9.5M funding to bring cultivated meat closer to price parity

TTP spinout Cellular Origins to focus on cell and gene therapies

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!